BIOLABO REAGENTS
www.biolabo.fr
MANUFACTURER:
BIOLABO SAS,
Les Hautes Rives,
02160, Maizy, France

Factor VIII Deficient Plasma

Immuno-depleted plasma for the determination of Factor VIII activity in citrated human plasma

REF 13308 **R1** 6 x 1 mL

IVD

Made In France

I: corresponds to significant modifications

TECHNICAL SUPPORT AND ORDERS

Tel: (33) 03 23 25 15 50

Fax : (33) 03 23 256 256
support@biolabo.fr
Latest revision: www.biolabo.fr

INTENDED USE

I This reagent is designated for professional use in laboratory (automated or semi-automated method). It allows the quantitative determination of Factor VIII activity in citrated human plasma.
This test is realized with reagents BIOLABO as follows:

REF 13660 and 13670: BIO-SIL (APTT Silica)
REF 13560 and 13570: BIO-CK (APTT Kaolin)
REF 13565: $CaCl_2$ Solution 0.025 M
REF 13883: Owren Köller buffer dilute reference, control and patient's plasmas.

GENERALITIES (1) (4) (5) (7) (8) (10) (11)

Factor VIII (antihemophilic factor A) is a glycoprotein present in the liver, spleen, kidneys and lymphocytes. It circulates in the plasma in the form of a non-covalent complex with Von Willebrand factor. The F.VIII is activated by Thrombin and F.Xa; the F.VIII accelerates the activation of the F.X by the F.IXa in the presence of phospholipids and Ca^{2+}.
There are pathological changes in the F.VIII in the following cases:
-Hemophilia A:
The seriousness of hemophilia is assessed on the basis of the concentration of F.VIII: C.

Severe hemophilia	< 0.1% (0.01 IU/mL)
Moderate hemophilia	1-5% (0.01 - 0.05 IU mL)
Hemophilia attenuated	5-40% (0.05 - 0. 40 IU/mL)

-Von Willebrand disease:
More or less pronounced decrease in the rate of F.VIII
-The elevation of the F.VIII rate is a risk factor for thrombosis, including venous thrombosis. This elevation is observed in case of thromboembolic complications, coronary atherosclerosis, renal failure, diabetes, inflammatory syndrome...
-There is a decrease in F.VIII in the presence of inhibitor of F.VIII

PRINCIPLE (1) (3)

The assay consists in the measurement of the clotting time, in the presence of cephalin and activator, of a system in which all the factors are present in excess except of factor VIII which is derived from the sample being tested.

REAGENTS

R1 **F-VIII** Deficient Plasma

Human Origin

Freeze dried citrated plasma without Factor VIII (removed by selective immune adsorption).

SAFETY CAUTIONS

- Material Safety Data Sheet is available upon request.
- Each donor unit used to manufacture this product was tested and found non-reactive for HbsAg, antibody to Hepatitis C and antibody to HIV-1/HIV-2.
- However, no test method can offer complete assurance that infectious agents are absent. All specimens or reagents from biological origin should be handled as potentially infectious, in accordance with good laboratory practices using appropriate precautions.
- Waste disposal: Respect legislation in force in the country.

I Any serious incident that has occurred in connection with the device is notified to the manufacturer and the competent authority of the Member State in which the user and/or patient is based.

REAGENTS PREPARATION

- Open the vial carefully and add exactly 1 mL of demineralized water**.**
- Recap and let stand for 15 minutes at room temperature.
- Before use, gently agitate to avoid the formation of foam.

STABILITY AND STORAGE

Stored away from light, well caped in the original vial at 2-8°C, when stored and used as described, reagents are stable:

Unopened:
- Until expiry date stated on the label of the kit.

Once opened:
- R1 must be reconstituted immediately.

I Once reconstituted, plasma is stable: 8 hours at 2-25°C.

SPECIMEN COLLECTION AND HANDLING (9) (12)

Citrated Plasma: Mix freshly drawn blood (9 Volumes) with buffered tri-sodium citrate solution 3.2% (1 volume).
Centrifuge for 10 min at 3000 g and extract supernatant.

Storage in plastic tube: 4h at 2-25°C

If quickly frozen: 15 days at -20°C, 1 month at -80°C (Thaw frozen plasmas at 37°C until complete thawing)

LIMITES (6)

Thrombin inhibitors (i.e. hirudin, argatroban …) present in the specimen to be tested may lead to under-estimation of the factor VIII activity in the specimen.

The presence of Lupus anticoagulants may lead to an under-estimation of Factor VIII activity in the specimen.

For a more comprehensive review of factors affecting this assay refer to the publication of Young D.S.

MATERIAL REQUIRED BUT NOT PROVIDED

1. Basic medical analysis laboratory equipment.
2. Automated or semi-automated coagulation analyzer

Manufacturer	Expiry date	In vitro diagnostic	Storage temperature	Dematerialized water	Biological risk
Product Reference	See Insert	Batch number	Store away from light	Sufficient for	Dilute with

CALIBRATION

- REF 13970: BIO CAL, reference plasma for calibration of coagulation tests

Calibration frequency depends on proper instrument functions and on the preservation of reagent.

QUALITY CONTROL

- REF 13971: COATROL1 Level 1
- REF 13972: COATROL 2 Level 2
- External quality control program.

It is recommended to control in the following cases:

- At least once a run
- At least once within 24 hours
- When changing vial of reagent
- After maintenance operations on the instrument

If control is out of range, apply following actions:

1. Prepare a fresh control serum and repeat the test
2. If control is still out of range, use a new vial of fresh calibrator
3. If control is still out of range, use a new vial of reagent and reassay

If control is still out of range, please contact BIOLABO technical support or your local Agent.

REFERENCE INTERVALS (2) (7)

Plasma (adult)	Usually 60-150%

Many factors may lead to increased F.VIII: C level:

- Use of birth control pills, pregnancy
- AVK and corticoid therapies
- Physical exercise, stress...

Each laboratory should establish its own normal ranges for the population that it serves.

PERFORMANCES

On automatic analyzer SOLEA 100 at 37°C:

Precision:

Intra-Assay N = 20	level 1	level 2
Mean %	127	52
S.D. %	6.6	2.9
C.V. %	5.2	5.6

Inter-Assay N = 20	level 1	level 2
Mean %	100	43
S.D. %	9.0	2.6
C.V. %	9.0	6.2

Detection limit: 6 % of Factor VIII

Measuring Range: from 20% (QL) to 135%

Interferences APTT Silica (sec):

Turbidity	No interference up to 0.404 abs
Bilirubin	Positive interference from 133 µmol/L
Hemoglobin	No interference up to 261 µmol/L

Other substances may interfere with the results (see § Limits)

Onboard stability: Deficient plasma is stable 4 hours

Calibration Stability: Re-calibrate each day

Make a new calibration when changing reagent batch, if quality control results are found out of the established range and after maintenance operations

PROCEDURE

Manual procedure on semi-automate BIO SOLEA 2, BIO SOLEA 4:

Prepare dilutions 1/10, 1/20, 1/40, 1/80 of REF 13970 BIO-CAL Reference Plasma in Owren Köller buffer

Pre-incubate PT Reagent at least 15 min at 37°C and mix gently.

Measure and record the clotting time for each dilution as follows:

Reference plasma diluted 1/10 to 1/80	0,1 mL
Deficient plasma	0,1 mL
APTT Reagent :	0,1mL
Incubate 3 minutes at 37°C.	
$CaCl_2$ 0,025 M :	0,1mL
The automatic countdown timer will start immediately after $CaCl_2$ addition and stop when the clot is formed.	

Do the same for controls and specimens to be tested (pre-diluted 1/10 in Owren Köller buffer):

Controls and specimens (diluted 1/10)	0,1 mL
Deficient Plasma	0,1 mL
APTT Reagent :	0,1mL
Incubate 3 minutes at 37°C.	
$CaCl_2$ 0,025 M :	0,1mL
The automatic countdown timer will start immediately after $CaCl_2$ addition and stop when the clot is formed.	

Automated procedure : Full detailed application available on request

- Performances and stability data have been validated on SOLEA 100 and Thrombolyzer Compact X (available on request).
- With manual procedure and on other automated coagulation analyzer, performances and stability data must be validated by user.
- Other validated applications or proposal are available on request.

CALCULATION

Manual procedure:

Plot a Standard Curve using results obtained with dilutions 1/10 to 1/80 of reference plasma

Concentration % = f (Clotting Time)

Read the concentration of controls and samples reporting clotting time on the graph.

Automated and semi-automated procedure:

Patients results (seconds) will be automatically converted in % of Deficient Factor according to calibration curve.

REFERENCES

(1) *SOULIER J.P., LARRIEU M-J.: Sang.* ***24****, 3, 205-215, 1953*

(2) *CAEN J., LARRIEU M-J., SAMAMA M.: Paris, L'Exp. Scient., 181, 1975*

(3) *ZACHARSKIL.R. ROSENSTEIN R.: "Standardisation of the one stage assay for F.VIII (antihemolytic factor". Am. J. Clin. Pathol.,* ***70****, 280-286, 1978*

(4) *MARDER V.J., MANNUCCI P.M., FIRKIN B.G., HOYER L.W., MEYER D.:"Standard nomenclkature for F.VIII and Von Willebrand Factor: a recommendation by the international Committee on thrombosis and haemostasis". Thromb. Haemostasis,* ***54****, 4, 871-872, 1985.*

(5) *SAMAMA M., CONARD J., HORELLOU M.H., LECOMPTE T.: "physiologie et exploration de l'hémostase" Paris: Doin,* ***81****, 109-112, 1990*

(6) *YOUNG D.S., Effect of Drugs on Clinical laboratory Tests, 4th Ed. (1995) p.3-254 à 3-257*

(7) *SAMPOL J., ARNOUX D., BOUTIERE B.: "manuel d'hemostase" Paris: Editions scientifiques et médicales ELSEVIER, 311-336, 379-381, 552-553, 608-609, 1995.*

(8) *KAMPHUINSEN P.W., EIKENBOOM J.C.J., BERTINA R.M.:"Elevated F.VIII levels and the risk of thrombosis". Artheioscl. Thromb. Vasc. Biol.,* ***21****, 731-738, 2001*

(9) *WOODHAMS B., GIRARDOT O., BLANCO M.J., COLESSE G., GOURMELIN Y.: "Stability of coagulation proteins in frozen plasma" Blood Coag. Fibrinolysis,* ***12****, 229-236, 2001*

(10) *WHITE G.C., ROSENDAAL F., ALEDORT L.M., LUSHER J.M., ROTSHILD C., INGERSLEV J.: "Definition in haemophilia-Recommendation of the Scientific Subcommittee on factor VIII and factor VIII of the Scientific and Standardization Committee of the international society on Thrombosis and haemostasis"Thromb. Haemostasis,* ***85****, 560, 2001*

(11) *FRESSINAUD E., MEYER D.: "La maladie de Willebrand: du diagnostic au traitement". Rev. Prat.,* ***55****, 2209-2218, 2005*

(12) *CLSI Document H21-A5: "Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular haemostasis assys; approved guideline". Fifth edition,* ***28****, 5, 2008*